跳至主要内容
临床试验/NCT04127318
NCT04127318撤回不适用

Evaluating the Effects of Low-moderate Intensity Pedaling During Immunotherapy Administration on Immune Biomarkers and Quality of Life

Rush University Medical Center2 个研究点 分布在 1 个国家开始时间: 2020年1月31日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Feasibility of Pedaling Concurrent to Immunotherapy Infusions

研究概览

简要总结

The purpose of this study is to determine the feasibility pedaling using an under-the desk bike during immunotherapy infusions. Also, the study hopes to evaluate how pedaling impacts quality of life and treatment response biomarkers. Lastly, the study will evaluate the relationships between treatment response and muscle mass which is evaluated with computerized tomography (CT) scans.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Minimum age of 18
  • Renal Cell Carcinoma, cutaneous malignancies (Melanoma, Merkel Cell Carcinoma or Squamous Cell CA) or bladder cancer.
  • Planned intravenous immunotherapy treatment (Pembrolizumab, Nivolumab, or combinations as clinically indicated by standards of care).
  • ECOG Performance Status of Grade 0-2
  • No uncontrolled cardiac disease

排除标准

  • ECOG Performance Status of Grade 3-5
  • Severe cardiac history or comorbidities (i.e. heart failure, clinically significant aortic stenosis, history of cardiac arrest, have a cardiac defibrillator, uncontrolled angina, uncontrolled arrhythmias, major heart surgery, stroke, or pulmonary embolus).
  • Chest pain or severe shortness of breath at rest or with physical activity.
  • Orthopedic impediments to exercise (i.e. joint immobility or lower extremity lymphedema).
  • Limitations to sustained exercise (i.e. bone metastases in the femur neck).
  • Severe arthritis (i.e. osteoarthritis or rheumatoid arthritis).
  • Patients will be excluded from study if their immunotherapy treatment requires the use of sedating antihistamines prior to treatment.

结局指标

主要结局

Feasibility of Pedaling Concurrent to Immunotherapy Infusions

时间窗: 12 weeks

The number of completed pedaling sessions as well as the ability of patients to meet goal pedaling intensities will be evaluated.

次要结局

  • Quality of life scores(12 weeks)
  • Treatment response biomarkers(12 weeks)
  • CT-derived sarcopenia rates(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验